Clinical trial
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
NCT00151398 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00151398 |
|---|---|
| Title | Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD) |
| Official title | A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | lecozotan SR, Donepezil |
| Enrollment | 229 |
| Start date | Oct 6, 2005 |
| Primary completion | Mar 15, 2008 |
| Completion | Mar 15, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | May 6, 2022 |
| Countries | Argentina, Australia, Canada, South Africa, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: